SPOTLIGHT -
April 22nd 2024
Per the agreement, Cellares will integrate and automate some of Bristol Myers Squibb’s CAR T-cell therapies into its Cell Shuttle program.
April 19th 2024
Acquisition includes rights to marketing in the European Economic Area, Thailand, South Korea, and other regions for oral treatment of mild to moderately severe dementia associated with Alzheimer disease.
April 12th 2024
Partnership also includes an agreement for Arvinas to sell its preclinical AR-V7 program to Novartis.
The takeover is contingent upon a minimum acceptance rate of 65% and other conditions outlined in the offer document.
April 10th 2024
Joint venture aims to implement Invenra’s B-Body bispecific antibody platform to enhance Astellas' research and development efforts.
The Quest to Fully Address Prescription Drug Affordability
The Medicare Part D cap won’t solve need for financial assistance.
Could a Rates Pivot By Fed Change Biotech’s Fate?
Such a scenario is one possibility as the bear market languishes on.
When to Utilize Commercial Outsourcing
When deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.
Will Recent Surge in M&A Dealmaking Save Biotech Sector?
The ‘blistering’ pace may further divide the haves from the have-nots.
Does the Biotech Sector Have Reason to Be Optimistic?
Over two years into a bear market, it still can’t catch a sustainable bid.
Biotech Challenges & Financing
Experts from Kallyope share biotech challenges they have faced and overcome as well as ways to go about securing funds in this exclusive Q&A.
Value Creation Through Portfolio-Based Corporate Strategy
Looking at corporate value through a portfolio lens provides an astute and reliable path to genuine value creation.
Biopharma M&A: Year in Review, Ripples Ahead
While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.
More than Ever, Data Will Dictate Future Fortunes
Is stock market outperformance for biotech still in the cards for 2023?
An Inside Look at Pharma Revenue Management
According to the 2023 State of Revenue Report, pharma companies are prioritizing digital transformation while struggling with inflation and supply chain disruptions.
Data Signals Some Green Shoots for Biotech in 2023
Chronicling the market’s rise and fall—and signs of potential recovery.
Biopharma Investment Implications: Looking Back and Forward
What a changing economy and related trends could mean for 2023.
Back in Person, Sparks Could Fly at Upcoming J.P. Morgan Conference
Will biopharma investment heat up and signal better fortunes for 2023?
The New Reality for Industry Dealmaking May be Setting In
Focus is on cash: who’s got it, who doesn’t, and what will it mean?
Discerning Dealmaking: Caution Flag Still Raised in Biopharma M&A Race
Big pharma’s finicky appetite for M&A comes as valuations of sellers soften. Though the pace of deals has picked up some, predicting just how long both sides will hold tight remains difficult.
All About the Rates: The Fallout of Fed Hikes for Biotech
As fundamentals improve, potential rate plateau could ignite growth.
Q&A With Greg Rotz, PLS Advisory Leader at PwC
Rotz discusses a report he co-authored for PwC about how life sciences companies perform on the S&P 500.
21st Annual Industry Audit: Pharma Performance Check
Our latest metrics tally across seven business-key measures uncovers some familiar players pacing the field in delivering shareholder value and getting the most from their investments.
The Biotech Rally Continues—What’s Fueling the Surge?
Biotech stocks and the indexes have staged an impressive recovery.
Q&A With Kim Barnes, Executive Vice President at Phacilitate
Barnes discusses alternative reimbursement plans for expensive, one-off therapies.
Navigating the Financial Meltdown for Biopharma
A review of pharma and biotech equity market, IPO, and M&A trends and outputs through the first half of 2022—and implications for the future as disruptions continue to have an impact.
Has Biotech Bottomed Out—and is Recent Recovery Sustainable?
A look at the driving factors behind renewed optimism.
Positive Outlook for Post-Pandemic Biotech
A recent analysis of the biotech market shows promising signs.
Q&A With Bryan Kobel, CEO, TC BioPharm
Kobel discusses taking a company public during a challenging time in the market.
A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs
COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a key strategic cog.
Biotech Performance Glance—and Promising Ripples for Recovery
A summary of key takeaways from EY’s new Beyond Borders report.
Surviving the Life Sciences Funding Cliff
Restructuring and ensuring the right talent is in place can help life sciences industry push through latest downward spiral.
Are We Closer Than Ever to a Biotech Bottom?
Some observations point to hope for an upturn.
Biotech Prospects for Stayin’ Alive During Correction
Living to fight another day, as potential investment spark looms.
Surviving Biotech’s Longest and Steepest Bear Market Ever
What will current stranglehold mean for industry down the line?